CSE:SIXW

Sixth Wave Presents Affinity Extraction Technology at the Premiere Gathering of North America Cannabis Entrepreneurs

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") announces the Company is participating in the Benzinga Cannabis Capital Conference hosted live and virtually on October 15, 2021. Dr. Jonathan Gluckman (CEO) will speak during the Conference's Virtual Track on Thursday, October 14, 2021, at 3:20 p.m. EST.

A link to Dr. Gluckman's pre-recorded presentation is now available on Sixth Wave's Website at https://www.sixthwave.com.

The Benzinga Cannabis Capital Conference in New York City is the premier North American gathering of cannabis entrepreneurs and investors held during a 2-Day Hybrid Event on October 14-15. The event will feature an interactive forum of live and On-Demand presentations from top CEOs, investors, and leaders in the cannabis space. Event registration is available at https://www.benzinga.com/events/cannabis/october-2021.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system and IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs™) label.

Sixth Wave can design, develop, and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our website at: https://www.sixthwave.com/.

ON BEHALF OF THE BOARD OF DIRECTORS
"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Investor Relations: 
Mark MacDonald 
mark@sixthwave.com 
902-489-7273

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99692

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sixth Wave Innovations

Sixth Wave Innovations

Overview

Sixth Wave Innovations (CSE:SIXW,OTCQB:SIXWF,FSE:AHUH) is a nanotechnology company that uses patented Molecularly Imprinted Polymers (MIPs) for detecting, capturing and purifying substances at the molecular level.

MIPs are synthetic polymers uniquely designed to capture and extract target materials from a background of other materials by a combination of engineered electrochemical methods to attract the materials to the polymer and templating or creating a pocket in the polymer that has the physical size and shape of the target material to ensure that only those materials are captured. Systems utilizing MIPs are developed and owned completely by Sixth Wave Innovations with multiple patented/patent pending protections in over 40 countries worldwide. With massive expertise in the chemical industry and broad vertical patents, there are huge market implications for commercial scaling and revenue opportunities.

Keep reading...Show less

Nanotechnology Using Molecularly Imprinted Polymers (MIPs) With Multi-Market Applications

Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×